Prostate Cancer

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

The trial’s presentation at ESMO 2025 emphasized postponement of castration-resistant progression, with Novartis targeting year-end submissions.